<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82007">
  <stage>Registered</stage>
  <submitdate>9/05/2007</submitdate>
  <approvaldate>10/05/2007</approvaldate>
  <actrnumber>ACTRN12607000250437</actrnumber>
  <trial_identification>
    <studytitle>Schizophrenia Treatment Adherence Investigation (STAI)</studytitle>
    <scientifictitle>Treatment review and feedback program to determine risk of poor medication adherence in patients with schizophrenia or schizoaffective disorder.</scientifictitle>
    <utrn />
    <trialacronym>STAI</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia or Schizoaffective disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This treatment review is designed to assess medication adherence in subjects with schizophrenia or schizoaffective disorder. Subjects will not be given any interventional treatments as part of this review. The duration of participant observation for this treatment review is 12 months.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome of this treatment review is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. </outcome>
      <timepoint>Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Reporting on the proportion of patients with schizophrenia who may be inappropriately clinically and/or medically treated in the context of their medication adherence risk status. 
</outcome>
      <timepoint>Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Quantifying any antipsychotic medication modification and relating this to the treatment review factors captured at baseline. 
</outcome>
      <timepoint>Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Relating the adherence risk status to the medications used and the actual acute exacerbation rate.</outcome>
      <timepoint>Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Clinical diagnosis of Schizophrenia or Schizoaffective Disorder according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition). Currently treated in an outpatient clinic. Over 18 years and able to provide informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>There is no exclusion criteria for this treatment review.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag Pty Ltd</primarysponsorname>
    <primarysponsoraddress>1-5 Khartoum Road,
North Ryde
NSW, 2133</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Janssen-Cilag Pty Ltd</fundingname>
      <fundingaddress>1-5 Khartoum Road,
North Ryde
NSW, 2133</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>N/A</fundingname>
      <fundingaddress>N/A</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Kendle Pty Limited</sponsorname>
      <sponsoraddress>156-158 Drummond Street,
Oakleigh,
Melbourne,
VIC 3166</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This treatment review aims to determine the risk of medication non-adherence in patients diagnosed with schizophrenia. Further, it aims to identify the proportion of patients receiving medical treatment that is inconsistent with their medication adherence risk status, assess the rate of modification of medication after the subject's adherence risk status is known, and to relate to the adherence risk status to their rate of sudden worsening of schizophrenia.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry limited</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peninsula Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queensland Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gold Coast Health Service District</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>ACT Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Bev Menner</name>
      <address>20 Atherton Rd, Oakleigh, Vic, 3166</address>
      <phone>+61 3 95677622</phone>
      <fax>+61 3 96548336</fax>
      <email>menner.bev@kendle.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Bev Menner</name>
      <address>20 Atherton Rd, Oakleigh, Vic, 3166</address>
      <phone>+61 3 95677622</phone>
      <fax>+61 3 96548336</fax>
      <email>menner.bev@kendle.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lilee Chew</name>
      <address>20 Atherton Rd, Oakleigh, Vic, 3166</address>
      <phone>+61395677631</phone>
      <fax>+61395677699</fax>
      <email>chew.lilee@kendle.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>